Trial · NCT02736955
Results by group37
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 37
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Monitored for Long-term Safety of Valbenazine | Valbenazine 40 mg | 35 | Participants | ||
| Number of Participants Monitored for Long-term Safety of Valbenazine | Valbenazine 80 mg | 117 | Participants | ||
| Number of Participants Monitored for Long-term Safety of Valbenazine | Valbenazine 40/80 mg | 8 | Participants | ||
| Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale | Valbenazine 40 mg | Baseline | 2 | Participants | |
| Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale | Valbenazine 80 mg | Baseline | 21 | Participants | |
| Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale | Valbenazine 40/80 mg | Baseline | 0 | Participants | |
| Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale | Valbenazine 40 mg | Week 12 | 15 | Participants | |
| Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale | Valbenazine 80 mg | Week 12 | 56 | Participants | |
| Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale | Valbenazine 40/80 mg | Week 12 | 3 | Participants | |
| Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale | Valbenazine 40 mg | Week 24 | 11 | Participants | |
| Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale | Valbenazine 80 mg | Week 24 | 56 | Participants | |
| Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale | Valbenazine 40/80 mg | Week 24 | 4 | Participants | |
| Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale | Valbenazine 40 mg | Week 36 | 7 | Participants | |
| Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale | Valbenazine 80 mg | Week 36 | 44 | Participants | |
| Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale | Valbenazine 40/80 mg | Week 36 | 2 | Participants | |
| Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale | Valbenazine 40 mg | Week 48 | 5 | Participants | |
| Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale | Valbenazine 80 mg | Week 48 | 29 | Participants | |
| Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale | Valbenazine 40/80 mg | Week 48 | 2 | Participants | |
| Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale | Valbenazine 40 mg | Week 60 | 2 | Participants | |
| Number of Participants With Clinical Response as Assessed by the Clinical Global Impression of Tardive Dyskinesia - Severity (CGI-TD-Severity) Scale | Valbenazine 80 mg | Week 60 | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02736955/results